

due diligence services for investors / acquisitions / co-operation agreements

as an independent third party we assess potential acquisition targets in pharmaceutical industry:

- r&d strategies
- r&d portfolios
- organisation and management of r&d
- regulatory compliance of projects and marketed products
- chances of developmental projects to reach the market

example:

objective: a non-european pharmaceutical company identified a german biotech company to acquire. p.ss.t was asked

- to assess the value of the r&d portfolio,
- to identify potential risks in the r&d projects
- to look after the regulatory compliance of marketed products

project realisation:

P.SS.T

- reviewed all internal documents (project status reports, investigator brochures, pre- and clinical study reports, network plan, master plans etc), assessed the status of the project (also in comparison to competitors) and provided an opinion upon the assets of r&d
- reviewed all registration dossiers of marketed products and latest correspondence with regulatory agencies and provided an statement on completeness of the documents and potential risks (e.g. to loose the marketing authorisation of older products because of lack of convincing evidence of proof of efficacy)

project outcome:

- the acquisition was successfully completed but
- 1.because of the detection of weak points in r&d, organisational changes in r&d were initiated

finally: **the acquisition price was reduced**